Targeted alpha therapy in the treatment of ovarian cancer
|Coordinator||VÄSTRA GÖTALANDS LÄNS LANDSTING - Avdelning för onkologi|
|Funding from Vinnova||SEK 2 000 000|
|Project duration||September 2017 - August 2020|
|Venture||Eurostars 2 medfinansiering|
Purpose and goal
The idea of this project is to develop a targeted alpha-particle radio-immunotherapy (TAT) based on astatine-211 conjugated to the monoclonal antibody (MAb) farletuzumab as a new drug for the treatment of ovarian cancer.
Expected results and effects
Our drug is based on an almost ideal radionuclide for intra cavitary treatment of small tumor aggregates, and thereby has potential to offer treatment of microscopic tumor clusters without significant acute toxicity, which would be a global breakthrough therapy within the field of radioimmunotherapy.
Planned approach and implementation
We will conduct the First-in-Man clinical trial in patients in complete clinical remission after second-line chemotherapy for recurrent ovarian carcinoma. The aim is to study pharmacokinetics (PK) and particularly bio-distribution; as well as safety and toxicity.